113 related articles for article (PubMed ID: 38657228)
1. Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing sarcoma.
Collins VJ; Ludwig KR; Nelson AE; Sundara Rajan S; Yeung C; Vulikh K; Isanogle KA; Mendoza A; Difilippantonio S; Karim BO; Caplen NJ; Heske CM
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38657228
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.
de Campos-Nebel M; Larripa I; González-Cid M
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824055
[TBL] [Abstract][Full Text] [Related]
3. DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Minchinton AI
Sci Rep; 2023 Aug; 13(1):12429. PubMed ID: 37528151
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle arrest and apoptosis are early events in radiosensitization of EWS::FLI1
Lin MY; Damron TA; Horton JA
Int J Radiat Biol; 2023; 99(10):1570-1583. PubMed ID: 36913323
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
7. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.
Gómez-Herreros F; Romero-Granados R; Zeng Z; Alvarez-Quilón A; Quintero C; Ju L; Umans L; Vermeire L; Huylebroeck D; Caldecott KW; Cortés-Ledesma F
PLoS Genet; 2013; 9(3):e1003226. PubMed ID: 23505375
[TBL] [Abstract][Full Text] [Related]
8. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
9. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.
Gibson AE; Yeung C; Issaq SH; Collins VJ; Gouzoulis M; Zhang Y; Ji J; Mendoza A; Heske CM
Oncogenesis; 2020 Sep; 9(9):80. PubMed ID: 32908120
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
12. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
Elife; 2020 Feb; 9():. PubMed ID: 32057297
[TBL] [Abstract][Full Text] [Related]
13. The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture.
Graca Marques J; Pavlovic B; Ngo QA; Pedot G; Roemmele M; Volken L; Kisele S; Perbet R; Wachtel M; Schäfer BW
Cancer Res; 2024 Jan; 84(2):241-257. PubMed ID: 37963210
[TBL] [Abstract][Full Text] [Related]
14. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
15. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
17. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
19. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
20. PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.
Zhang Y; Xie C; Li A; Liu X; Xing Y; Shen J; Huo Z; Zhou S; Liu X; Xie Y; Cao W; Ma Y; Xu R; Cai S; Tang X; Ma D
Am J Transl Res; 2019; 11(8):5134-5149. PubMed ID: 31497229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
